EnaBILEing Growth in the Fetal Liver

Goessling, Wolfram; North, Trista E.

doi:10.1016/j.stem.2016.03.019

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More information and research need to be carried out to find ways to increase the relative expression of CYP7B1 which would increase the value of the alternative BA synthetic pathway in the treatment and prevention of end stage liver disease. the HSC pool in the bone marrow remains in the quiescent bone marrow niche (Goessling and North, 2016). In a recent study, the rapid proliferation of HSCs in the mouse FL exhibited elevated rates of protein synthesis that was not accompanied by increased ER stress, upregulation of ER chaperones or stress response genes.…”

Section: The Alternative Ba Synthetic Pathway Is Important For the Enmentioning

confidence: 99%

Targeting the alternative bile acid synthetic pathway for metabolic diseases

et al. 2020

View full text Add to dashboard Cite

The gut microbiota is profoundly involved in glucose and lipid metabolism, in part by regulating bile acid (BA) metabolism and affecting multiple BA-receptor signaling pathways. BAs are synthesized in the liver by multi-step reactions catalyzed via two distinct routes, the classical pathway (producing the 12α-hydroxylated primary BA, cholic acid), and the alternative pathway (producing the non-12α-hydroxylated primary BA, chenodeoxycholic acid). BA synthesis and excretion is a major pathway of cholesterol and lipid catabolism, and thus, is implicated in a variety of metabolic diseases including obesity, insulin resistance, and nonalcoholic fatty liver disease. Additionally, both oxysterols and BAs function as signaling molecules that activate multiple nuclear and membrane receptor-mediated signaling pathways in various tissues, regulating glucose, lipid homeostasis, inflammation, and energy expenditure. Modulating BA synthesis and composition to regulate BA signaling is an interesting and novel direction for developing therapies for metabolic disease. In this review, we summarize the most recent findings on the role of BA synthetic pathways, with a focus on the role of the alternative pathway, which has been under-investigated, in treating hyperglycemia and fatty liver disease. We also discuss future perspectives to develop promising pharmacological strategies targeting the alternative BA synthetic pathway for the treatment of metabolic diseases.

show abstract

Section: The Alternative Ba Synthetic Pathway Is Important For the Enmentioning

confidence: 99%